S&P 500   3,933.92
DOW   33,597.92
QQQ   280.53
How To Be Persuasive With Your Body Language
Minerals for Green Revolution a Massive Investor Opportunity (Ad)
How to Play Apple and Amazon Heading in 2023
Low Beta, High Yield Campbell Soup Company Is Mmm Mmm Good
Minerals for Green Revolution a Massive Investor Opportunity (Ad)
Microsoft strikes 10-year deal with Nintendo on Call of Duty
Could trawler cams help save world's dwindling fish stocks?
Minerals for Green Revolution a Massive Investor Opportunity (Ad)
Southwest Airlines brings back dividend as travel rebounds
Closing prices for crude oil, gold and other commodities
S&P 500   3,933.92
DOW   33,597.92
QQQ   280.53
How To Be Persuasive With Your Body Language
Minerals for Green Revolution a Massive Investor Opportunity (Ad)
How to Play Apple and Amazon Heading in 2023
Low Beta, High Yield Campbell Soup Company Is Mmm Mmm Good
Minerals for Green Revolution a Massive Investor Opportunity (Ad)
Microsoft strikes 10-year deal with Nintendo on Call of Duty
Could trawler cams help save world's dwindling fish stocks?
Minerals for Green Revolution a Massive Investor Opportunity (Ad)
Southwest Airlines brings back dividend as travel rebounds
Closing prices for crude oil, gold and other commodities
S&P 500   3,933.92
DOW   33,597.92
QQQ   280.53
How To Be Persuasive With Your Body Language
Minerals for Green Revolution a Massive Investor Opportunity (Ad)
How to Play Apple and Amazon Heading in 2023
Low Beta, High Yield Campbell Soup Company Is Mmm Mmm Good
Minerals for Green Revolution a Massive Investor Opportunity (Ad)
Microsoft strikes 10-year deal with Nintendo on Call of Duty
Could trawler cams help save world's dwindling fish stocks?
Minerals for Green Revolution a Massive Investor Opportunity (Ad)
Southwest Airlines brings back dividend as travel rebounds
Closing prices for crude oil, gold and other commodities
S&P 500   3,933.92
DOW   33,597.92
QQQ   280.53
How To Be Persuasive With Your Body Language
Minerals for Green Revolution a Massive Investor Opportunity (Ad)
How to Play Apple and Amazon Heading in 2023
Low Beta, High Yield Campbell Soup Company Is Mmm Mmm Good
Minerals for Green Revolution a Massive Investor Opportunity (Ad)
Microsoft strikes 10-year deal with Nintendo on Call of Duty
Could trawler cams help save world's dwindling fish stocks?
Minerals for Green Revolution a Massive Investor Opportunity (Ad)
Southwest Airlines brings back dividend as travel rebounds
Closing prices for crude oil, gold and other commodities
NASDAQ:ESPR

Esperion Therapeutics - ESPR Stock Forecast, Price & News

$6.33
-1.11 (-14.92%)
(As of 12/7/2022 12:00 AM ET)
Add
Compare
Today's Range
$6.13
$8.87
50-Day Range
$6.33
$8.56
52-Week Range
$3.28
$8.87
Volume
23.10 million shs
Average Volume
971,174 shs
Market Capitalization
$466.39 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$10.43

Esperion Therapeutics MarketRank™ Forecast

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
64.7% Upside
$10.43 Price Target
Short Interest
Bearish
19.04% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-2.76
Upright™ Environmental Score
News Sentiment
0.51mentions of Esperion Therapeutics in the last 14 days
Based on 7 Articles This Week
Insider Trading
Selling Shares
$32,563 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($3.65) to ($1.75) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.92 out of 5 stars

Medical Sector

837th out of 1,027 stocks

Pharmaceutical Preparations Industry

411th out of 503 stocks

ESPR stock logo

About Esperion Therapeutics (NASDAQ:ESPR) Stock

Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia. The company has a license and collaboration agreement with Daiichi Sankyo Europe GmbH; and Serometrix to in-license its oral, small molecule PCSK9 inhibitor program. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.

Receive ESPR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Esperion Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ESPR Stock News Headlines

Esperion Therapeutics (NASDAQ:ESPR) Trading 6.4% Higher
China Has Stunning Lithium Chokehold On U.S.
What's happening now is dangerous. The U.S. barely has any lithium so desperately needed for our military's equipment. China controls 80% of the world's lithium. If the communist country decides to withhold it from the U.S., our military could be brought to its knees.
Xeris (XERS), Horizon to Develop Ready-to-Use Teprotumumab
Esperion Appoints Ben Halladay Chief Financial Officer
China Has Stunning Lithium Chokehold On U.S.
What's happening now is dangerous. The U.S. barely has any lithium so desperately needed for our military's equipment. China controls 80% of the world's lithium. If the communist country decides to withhold it from the U.S., our military could be brought to its knees.
Recap: Esperion Therapeutics Q3 Earnings
Esperion Hosting Virtual Research & Development Day
ESPR Esperion Therapeutics, Inc.
See More Headlines
Receive ESPR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Esperion Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ESPR Company Calendar

Last Earnings
11/02/2021
Today
12/08/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
2/28/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ESPR
Fax
N/A
Employees
218
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$10.43
High Stock Price Forecast
$22.00
Low Stock Price Forecast
$5.00
Forecasted Upside/Downside
+64.7%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
5 Analysts

Profitability

Net Income
$-269,110,000.00
Net Margins
-337.63%
Pretax Margin
-337.63%

Debt

Sales & Book Value

Annual Sales
$78.45 million
Book Value
($3.23) per share

Miscellaneous

Free Float
71,252,000
Market Cap
$466.39 million
Optionable
Optionable
Beta
0.22

Key Executives

  • Mr. Sheldon L. Koenig (Age 56)
    Pres, CEO & Director
    Comp: $728.91k
  • Dr. JoAnne Micale Foody FACC (Age 57)
    M.D., Chief Medical Officer
    Comp: $471.86k
  • Mr. Benjamin Halladay M.B.A.
    Chief Financial Officer
  • Mr. Kenneth J. Fiorelli
    Chief Technical Operations Officer
  • Mr. Benjamin O. Looker (Age 40)
    Gen. Counsel
  • Ms. Betty Jean Swartz
    Chief Strategy Officer
  • Mr. Eric J. Warren R.Ph. (Age 50)
    Chief Commercial Officer













ESPR Stock - Frequently Asked Questions

Should I buy or sell Esperion Therapeutics stock right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Esperion Therapeutics in the last year. There are currently 2 sell ratings, 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" ESPR shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ESPR, but not buy additional shares or sell existing shares.
View ESPR analyst ratings
or view top-rated stocks.

What is Esperion Therapeutics' stock price forecast for 2023?

5 equities research analysts have issued 12-month price targets for Esperion Therapeutics' stock. Their ESPR share price forecasts range from $5.00 to $22.00. On average, they expect the company's stock price to reach $10.43 in the next twelve months. This suggests a possible upside of 64.7% from the stock's current price.
View analysts price targets for ESPR
or view top-rated stocks among Wall Street analysts.

How have ESPR shares performed in 2022?

Esperion Therapeutics' stock was trading at $5.00 on January 1st, 2022. Since then, ESPR shares have increased by 26.6% and is now trading at $6.33.
View the best growth stocks for 2022 here
.

When is Esperion Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 28th 2023.
View our ESPR earnings forecast
.

How were Esperion Therapeutics' earnings last quarter?

Esperion Therapeutics, Inc. (NASDAQ:ESPR) announced its quarterly earnings data on Tuesday, November, 2nd. The biopharmaceutical company reported ($2.62) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.86) by $0.24. The biopharmaceutical company earned $14.41 million during the quarter, compared to analysts' expectations of $12.31 million. During the same period in the prior year, the business earned ($3.07) earnings per share.

What is Tim Mayleben's approval rating as Esperion Therapeutics' CEO?

20 employees have rated Esperion Therapeutics Chief Executive Officer Tim Mayleben on Glassdoor.com. Tim Mayleben has an approval rating of 80% among the company's employees.

What other stocks do shareholders of Esperion Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Esperion Therapeutics investors own include ALDW (ALDW), Targa Resources (TRGP), Navios Maritime Partners (NMM), NVIDIA (nvda), Micron Technology (MU), SFL (SFL), Gilead Sciences (GILD), Boeing (BA), Alibaba Group (BABA) and BioMarin Pharmaceutical (bmrn).

What is Esperion Therapeutics' stock symbol?

Esperion Therapeutics trades on the NASDAQ under the ticker symbol "ESPR."

Who are Esperion Therapeutics' major shareholders?

Esperion Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include Bellevue Group AG (5.73%), Vanguard Group Inc. (5.48%), State Street Corp (2.08%), Platinum Investment Management Ltd. (1.94%), Two Sigma Advisers LP (1.47%) and Two Sigma Investments LP (1.45%). Insiders that own company stock include Eric Warren, Joanne M Foody, Sheldon L Koenig, Target N V Biotech and Timothy M Mayleben.
View institutional ownership trends
.

How do I buy shares of Esperion Therapeutics?

Shares of ESPR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Esperion Therapeutics' stock price today?

One share of ESPR stock can currently be purchased for approximately $6.33.

How much money does Esperion Therapeutics make?

Esperion Therapeutics (NASDAQ:ESPR) has a market capitalization of $466.42 million and generates $78.45 million in revenue each year. The biopharmaceutical company earns $-269,110,000.00 in net income (profit) each year or ($4.56) on an earnings per share basis.

How many employees does Esperion Therapeutics have?

The company employs 218 workers across the globe.

How can I contact Esperion Therapeutics?

Esperion Therapeutics' mailing address is 3891 RANCHERO DRIVE SUITE 150, ANN ARBOR MI, 48108. The official website for the company is www.esperion.com. The biopharmaceutical company can be reached via phone at (734) 887-3903 or via email at ir@esperion.com.

This page (NASDAQ:ESPR) was last updated on 12/8/2022 by MarketBeat.com Staff